COST EFFECTIVENESS OF CETUXIMAB AND PANITUMUMAB FOR FIRST-LINE RAS WT METASTATIC COLORECAL CANCER

被引：1
|
作者：
Tikhonova, I [1 ]
Hoyle, M. [1 ]
Snowsill, T. [1 ]
Crathorne, L. [1 ]
Varley-Campbell, J. [1 ]
Peters, J. [1 ]
Briscoe, S. [1 ]
Bond, M. [1 ]
Huxley, N. [1 ]
机构：
[1] Univ Exeter, Exeter, Devon, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1612
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN113
引用
收藏
页码：A154 / A154
页数：1
相关论文
共 50 条
  • [21] Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America
    Pescott, Chris
    Kasle, Adam
    Esteso, Federico
    Stefani, Stephen
    Brust, Leandro
    Pinto, Jose
    Tilli, Malena
    Massello, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [22] Cost-utility analysis of panitumumab use compared with cetuximab and bevacizumab for the first-line therapy of wild-type RAS metastatic colorectal cancer in the Peruvian health system.
    Milton, Valderrama
    Apolaya-Segura, Moises
    Montenegro, Paola Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
    Carvalho, Adriana Camargo
    Leal, Frederico
    Sasse, Andre Deeke
    PLOS ONE, 2017, 12 (04):
  • [24] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Miguel Jhonatan Sotelo
    Beatriz García-Paredes
    Carlos Aguado
    Javier Sastre
    Eduardo Díaz-Rubio
    World Journal of Gastroenterology, 2014, (15) : 4208 - 4219
  • [25] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Sotelo, Miguel Jhonatan
    Garcia-Paredes, Beatriz
    Aguado, Carlos
    Sastre, Javier
    Diaz-Rubio, Eduardo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4208 - 4219
  • [26] Costs of adverse event management associated with first-line cetuximab or panitumumab in patients with metastatic colorectal cancer in Spain.
    Grana Suarez, Begona
    Tarazona, Noelia
    Duran Moran, Olga
    Fernandez Gonzalez, Ana
    De los Santos Real, Heidi
    Pescott, Chris P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 83 - 83
  • [27] Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
    Meinolf Karthaus
    Ralf-Dieter Hofheinz
    Laurent Mineur
    Henry Letocha
    Richard Greil
    Josef Thaler
    Eva Fernebro
    Kelly S Oliner
    Michael Boedigheimer
    Brian Twomey
    Ying Zhang
    Gaston Demonty
    Claus-Henning Köhne
    British Journal of Cancer, 2016, 115 : 1215 - 1222
  • [28] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE
    Gherardi, A.
    Masia, C.
    Plommet, N.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A738
  • [29] Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
    Attard, C. L.
    Brown, S.
    Alloul, K.
    Moore, M. J.
    CURRENT ONCOLOGY, 2014, 21 (01) : E41 - E51
  • [30] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
12345